In this study, we aimed to seek evidence for the rational combination therapy of Rapa and Osi in NSCLC cells based on the MAPK/ERK, Akt/mTOR, and PARP signaling pathways, providing a reference for further research on the combination therapy of Rapa and Osi in NSCLC. Here, MAPK1 is linked to non-small cell lung carcinoma.